65,437 trials
Cholera
Primary: Stool Output Volume During Treatment Period. — 9.82; 9.31; 5.69; 7.29 ml/kg·h-1 — p=0.003
Stargardt's Macular Dystrophy
Primary: Mean Rate of Change in the Area of Ellipsoid Zone Defect From Baseline Through Month 18 — 0.6383; 0.6644 mm^2/18 months — p=0.8669
Cystic Fibrosis
Primary: Maximum Plasma Concentration (Cmax) of Brensocatib on Day 1 — 62.4; 136; 338 nanograms per milliliter (ng/mL)
Pneumococcal Infection
Primary: Percentage of Participants With Solicited Injection-site Adverse Events (AEs) — 24.3; 16.4; 67.7; 54.5 Percentage of Participants
Pregnancy in Adolescence · HIV
Primary: Abstinence Attitudes — 4.18; 4.17; 4.17; 4.26 score on a scale
Diabetic Retinopathy · Diabetic Blindness
Primary: Number of Participant Who Had Baseline Eye Exam — 33 Participants
Bowel Preparation Before Colonoscopy
Primary: Number of Participants With Adequate Bowel Preparation — 111; 111 Participants — p=0.007
Migraine
Primary: Feasibility of TeleBMM — 14.2 Treatment Components Completed
Bronchopulmonary Dysplasia
Primary: Safety as Determined by Adverse Event Experienced by Participants — 71; 83; 53; 60 Events
Heart Failure · Fluid Overload
Primary: AUClast — 12470.092; 11684.297 ng*hr/mL
Obesity · Weight Loss
Primary: Weight Change — 7.93; 9.17; 8.19; 9.36 percentage of weight change
Tracheostomy
Primary: Heart Rate — 84.10; 84.33 beats per minute — p=0.87
Coronary Arterial Disease (CAD)
Primary: 888 Number of Participants With Major Adverse Cardiac Events (MACE) at 30 Days — 0 participants
Low Back Pain
Primary: Low Back Pain Intensity — 1.24; 1.73 units on a scale
Multiple Sclerosis
Primary: Impact of Spasticity, Measured by the Multiple Sclerosis Spasticity Scale-88 — -16.11; -15.83 units on a scale